$ALKS

Alkermes officer Gaffin proposes $83.5K share sale

Alkermes officer David Gaffin proposed selling 2,034 shares worth $83.5K, with a planned sale date of October 2, 2026. He previously sold 2,034 shares on four occasions between June and September 2026, with proceeds ranging from $87.6K to $109.9K. The company's outstanding shares total 167.8M.

Original reporting
Published Oct 2, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 10:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The disclosed sale is small relative to market cap and likely has limited price impact.

02

Market read

A modest insider sell with limited trading relevance.

03

What to watch

Potential upcoming corporate events or earnings that could dominate price action.

Relevance 4/10Novelty 2/10Timing: today

Background

Form 4 filings disclose insider transactions and are monitored for potential signals about company outlook.

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Officer David Joseph Gaffin filed a Form 4 proposing to sell 2,034 shares worth about $83.5K on Oct 2, 2026.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The transaction size is modest ($83K) and represents a typical insider liquidity event, which usually nudges the stock lower.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. markets where ALKS trades.

Low global relevance.

Counterpoint

The sale could be a routine liquidity move and may not affect price.

Key entities

  • David Joseph Gaffin

    Alkermes plc officer filing the sale.

Related articles

$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.